A novel multitarget stool RNA test for colorectal cancer screening achieved a sensitivity of 100% for CRC and 44% for advanced adenomas in patients aged 45 to 49, according to data from the CRC-PREVENT trial.
This younger age bracket, which made up 24% of the full study population, are now included in CRC screening recommendations, but until now, have not been specifically studied. Noninvasive screening test efficacy data are lacking for this age group, according to senior investigator David S. Lieberman, MD, a professor of medicine and former chief of gastroenterology at Oregon Health & Science University, in Portland.